A group of 157 patients, classified as WHO grade 3 anaplastic astrocytoma (78.3%) and WHO grade 2 diffuse astrocytoma (21.7%), participated in a multicenter study to explore the impact of EGFR amplification and TERT-promotor mutation on overall survival (OS). This evidence concerns the gene EGFR and diffuse astrocytoma.